CF in the Media

Celine Dion Concert Adds Tomorrows with CF Foundation

January 28, 2013 | Cystic Fibrosis Foundation

Celine Dion, the best-selling female music artist of all time, wowed a packed house of 4,000 guests during a special performance that benefited the Cystic Fibrosis Foundation at Caesars Palace in Las Vegas on January 20.

The once-in-a-lifetime event was made possible through a friendship and commitment of Gary Loveman, CEO of Caesars Entertainment Corporation, Dion and the live entertainment group AEG Live.

Adding Tomorrows with Celine Dion raised $1.5 million and brought together leaders in the fight against cystic fibrosis, including devoted friends of the Milestones major giving campaign, dedicated volunteers and families affected by the disease.

Read more


Mahopac girl's best defense against cystic fibrosis: keep moving

February 24, 2013 | Barbara Livingston Nackman, Lohud.com

On the soccer field Jacqueline Stack blends in with the youngsters on her team, passing the ball back and forth before making a solid kick.

But she’s doing much more than merely playing a game. Jacqueline is also staving off a serious medical condition and raising money for groundbreaking medical research.

The 12-year-old knows that building her physical strength and acuity helps her combat the life-threatening disease she was diagnosed with at eight months old.

“My friends help me a lot — and they are fun,” she said.

Jacqueline, her family and friends have banded together for more than a decade to raise more than
$1 million for research and education.

Read more


FDA Grants First Breakthrough Therapy Designations to Cystic Fibrosis Drugs

January 15, 2013 | Randi Hernandez, Specialty Pharmacy Times

The FDA granted the first-ever Breakthrough Therapy Designations to 2 cystic fibrosis medications from Vertex Pharmaceuticals. The first designation was given to Kalydeco (ivacaftor), a drug that is already approved by the FDA to treat patients 6 years and older who have the G551D mutation. This drug was given the designation for its potential new indications. The other designation was given to Kalydeco in combination with investigational agent VX-809 to treat cystic fibrosis patients who have 2 copies of F508del, the most common mutation in cystic fibrosis.

Read more


Sequencing Microbial Genes to Find Clues About Cystic Fibrosis

January 15, 2013 | Wynne Parry , New York Genome Center

The lungs of people with cystic fibrosis are known to be havens for microbes, including those that wouldn't stand a chance in healthy lungs. Research currently underway is finding an unexpected abundance of these bugs in young patients.

Read more


The Most Important New Drug Of 2012

December 27, 2012 | Matthew Herper, Forbes

The Food and Drug Administration looks set for a great 2012; with a few days left to go, it has approved 40 new drugs and vaccines, one of the most impressive totals ever, according to data from Pharmaceutical Approvals Monthly and FDA press releases. In this haul, one medicine stands out for its scientific and medical importance.

Read more